financetom
Business
financetom
/
Business
/
IOC Q4FY21: Seeing 15% impact on demand due to 2nd wave of COVID, says management
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IOC Q4FY21: Seeing 15% impact on demand due to 2nd wave of COVID, says management
May 20, 2021 2:37 AM

Indian Oil Corporation (IOC), India's biggest oil firm, on Wednesday reported a net profit of Rs 8,781.30 crore for the January-March quarter, helped by higher refining margins.

Detailing the numbers, Shrikant Madhav Vaidya, Chairman of the company said that there has been a 15 percent impact on demand due to the second wave of COVID. However, he clarified that the impact is not as much as it was last year.

“Last year there was a nationwide lockdown due to which the refinery runs had come to nearly 47-49 percent in the month of April. This year because different geographies have different type of lockdown the refinery runs in April were at about 96 percent and in the month of May it is 84 percent. So 15 percent is the demand destruction that we are seeing at this point of time,” he said in an interview to CNBC-TV18.

Vaidya said that gasoline and diesel cracks are between USD 4-5/barrel, adding that the Singapore GRM currently is at about USD 1.79/barrel.

He also said that the company was able to ramp up capacities in the petchem segment beyond 100 percent and the spreads too are doing well. “Combined with the spreads and the 100 percent capacity utilization, we have been able to register good petchem margins,” he said.

The company’s current debt stands at Rs 1.02 lakh crore. However, he said that the debt will remain at the same level despite planned capex of around Rs 26,000 crore.

Vaidya also said that the company is making investments in hydrogen and electric vehicles.

Watch the video for more.

(Edited by : Pranati Deva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NextDecade, EQT Ink 20-Year LNG Supply Agreement for Rio Grande Train 5
NextDecade, EQT Ink 20-Year LNG Supply Agreement for Rio Grande Train 5
Sep 3, 2025
05:46 PM EDT, 09/03/2025 (MT Newswires) -- NextDecade ( NEXT ) said late Wednesday that it has entered a 20-year deal to deliver 1.5 million tonnes per annum of liquefied natural gas to EQT (EQT) from its planned Rio Grande LNG Train 5 facility in Texas. The agreement increases Train 5's secured capacity to 3.5 MTPA, with NextDecade ( NEXT...
BRIEF-LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness
BRIEF-LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness
Sep 3, 2025
Sept 3 (Reuters) - LifeVantage Corp ( LFVN ): * LIFEVANTAGE ANNOUNCES ACQUISITION OF LOVEBIOME, EXPANDING LEADERSHIP IN DIRECT SALES, MICROBIOME HEALTH AND WELLNESS * LIFEVANTAGE CORP ( LFVN ) - ACQUISITION EXPECTED TO BE ACCRETIVE TO ADJUSTED EPS AND ADJUSTED EBITDA IN YEAR ONE Source text: Further company coverage: ...
Babcock & Wilcox Enterprises Regains Compliance With NYSE Listing Rule
Babcock & Wilcox Enterprises Regains Compliance With NYSE Listing Rule
Sep 3, 2025
05:50 PM EDT, 09/03/2025 (MT Newswires) -- Babcock & Wilcox Enterprises ( BW ) said late Wednesday it regained compliance with the New York Stock Exchange's listing requirement of maintaining a minimum average share bid price of $1 for 30 trading days. ...
Avadel Pharmaceuticals Gets Exclusive License From XWPharma for Sleep Disorder Treatment
Avadel Pharmaceuticals Gets Exclusive License From XWPharma for Sleep Disorder Treatment
Sep 3, 2025
05:49 PM EDT, 09/03/2025 (MT Newswires) -- Avadel Pharmaceuticals ( AVDL ) secured an exclusive license to develop and commercialize XWPharma's sleep disorder treatment, valiloxybate, including a $20 million upfront payment. Avadel gains the global rights, excluding mainland China, Hong Kong and Macau, and XWPharma is eligible for development and regulatory milestone payments of up to $30 million, the companies...
Copyright 2023-2026 - www.financetom.com All Rights Reserved